JP2024175003A5 - - Google Patents

Download PDF

Info

Publication number
JP2024175003A5
JP2024175003A5 JP2024158123A JP2024158123A JP2024175003A5 JP 2024175003 A5 JP2024175003 A5 JP 2024175003A5 JP 2024158123 A JP2024158123 A JP 2024158123A JP 2024158123 A JP2024158123 A JP 2024158123A JP 2024175003 A5 JP2024175003 A5 JP 2024175003A5
Authority
JP
Japan
Prior art keywords
monoclonal
antibody
amino acid
presented
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024158123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024175003A (ja
Filing date
Publication date
Priority claimed from JP2021526461A external-priority patent/JP7619941B2/ja
Application filed filed Critical
Publication of JP2024175003A publication Critical patent/JP2024175003A/ja
Publication of JP2024175003A5 publication Critical patent/JP2024175003A5/ja
Pending legal-status Critical Current

Links

JP2024158123A 2018-11-14 2024-09-12 Cd25抗体 Pending JP2024175003A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862767405P 2018-11-14 2018-11-14
US62/767,405 2018-11-14
JP2021526461A JP7619941B2 (ja) 2018-11-14 2019-11-14 Cd25抗体
PCT/US2019/061552 WO2020102591A1 (en) 2018-11-14 2019-11-14 Cd25 antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021526461A Division JP7619941B2 (ja) 2018-11-14 2019-11-14 Cd25抗体

Publications (2)

Publication Number Publication Date
JP2024175003A JP2024175003A (ja) 2024-12-17
JP2024175003A5 true JP2024175003A5 (https=) 2025-04-03

Family

ID=70730731

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526461A Active JP7619941B2 (ja) 2018-11-14 2019-11-14 Cd25抗体
JP2024158123A Pending JP2024175003A (ja) 2018-11-14 2024-09-12 Cd25抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021526461A Active JP7619941B2 (ja) 2018-11-14 2019-11-14 Cd25抗体

Country Status (6)

Country Link
US (2) US12215163B2 (https=)
EP (1) EP3880227A4 (https=)
JP (2) JP7619941B2 (https=)
CN (1) CN113677359A (https=)
CA (1) CA3120096A1 (https=)
WO (1) WO2020102591A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
MX2022001065A (es) * 2019-07-30 2022-02-14 Shanghai Hansoh Biomedical Co Ltd Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
US20230049732A1 (en) * 2019-12-30 2023-02-16 University Of Louisville Research Foundation, Inc. Virus-like particle binding agents, related compositions, and related methods
CA3201423A1 (en) 2020-11-13 2022-05-19 Ibio, Inc. Cd25 antibodies
WO2022235295A1 (en) * 2021-05-07 2022-11-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
JP2024532790A (ja) * 2021-08-09 2024-09-10 南京▲諾▼艾新生物技▲術▼有限公司 組換え抗ヒトcd25抗体及びその使用
CA3228786A1 (en) * 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd25 antibody
CN118829654A (zh) * 2021-12-29 2024-10-22 舒泰神(加州)生物科技有限公司 特异性识别C5aR1的抗体及其应用
US20250154268A1 (en) * 2022-01-17 2025-05-15 Nona Biosciences (Suzhou) Co., Ltd. Antibody targeting cd25, and preparation method therefor and use thereof
CN119451978A (zh) 2022-07-01 2025-02-14 神经基因治疗公司 Neo-2/15变体及其用于优先刺激T调节细胞的用途
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
TW202509067A (zh) * 2023-04-11 2025-03-01 大陸商蘇州創勝醫藥集團有限公司 抗cd25抗體及其用途
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117050165B (zh) * 2023-08-14 2025-03-25 三优生物医药(上海)有限公司 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN119331099B (zh) * 2024-11-06 2025-12-16 郑州伊美诺生物技术有限公司 抗嗜酸性粒细胞过氧化物酶的单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
CN107129524B (zh) * 2007-09-25 2023-11-21 田园温室气体研究有限公司 用于抑制微生物细胞的疫苗和疫苗组分
WO2011051327A2 (en) * 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2970486B1 (en) * 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016179212A1 (en) * 2015-05-05 2016-11-10 Albert Einstein College Of Medicine, Inc. Antibody therapeutics against filovirus infections and uses thereof
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN110856446A (zh) 2017-04-18 2020-02-28 阿法姆海外股份有限公司 抗pd-l1抗体及其用途
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2024175003A5 (https=)
JPWO2020102591A5 (https=)
JP2021534096A5 (https=)
RU2017104813A (ru) Молекулы со специфичностью к cd45 и cd79
JP2018521638A5 (https=)
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2020037555A5 (https=)
JP2021533159A5 (https=)
JP2017528476A5 (https=)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2020500834A5 (https=)
JP2025032102A5 (https=)
JP2024024114A5 (https=)
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
RU2014153440A (ru) Антитела против cd26 и их применение
JP2020502233A5 (https=)
JP2024109911A5 (https=)
JP2022501065A5 (https=)
JP2020531003A5 (https=)
JPWO2020033664A5 (https=)
JP2023103352A5 (https=)
JPWO2022111425A5 (https=)
JPWO2023091614A5 (https=)